Pegaptanib: A novel approach to ocular neovascularization

Annals of Pharmacotherapy

Volumn 40, Issue 7-8, 2006, Pages 1322-1326

  Chapman, Julie A ^a,b   Beckey, Cherylyn ^c  

^a Clinical Pharmacy Services   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Age related macular degeneration; Ocular neovascularization; Pegaptanib; Vascular endothelial growth factor

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; PEGAPTANIB; PLACEBO; RANIBIZUMAB;

CATARACT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA EDEMA; DISEASE CLASSIFICATION; DISEASE COURSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; EYE DISCHARGE; EYE PAIN; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; INFLAMMATION; NEOVASCULARIZATION (PATHOLOGY); PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; STAPHYLOCOCCUS EPIDERMIDIS; SYSTEMATIC REVIEW; THROMBOEMBOLISM; VISUAL DISORDER; VITREOUS FLOATERS; VITREOUS OPACITY;

ANIMALS; APTAMERS, NUCLEOTIDE; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; HUMANS; MACULAR DEGENERATION; RETINAL NEOVASCULARIZATION; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 33747007916     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G604     Document Type: Review

References (16)

1. Friedman DS, O'Colemain BJ, Muñoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122: 564-72.
2. Krzystolik MG, Woodcome HA, Reddy U. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration [protocol]. Cochrane Collaboration 2005;3.
3. Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Arch Ophthalmol 1999;117:1329-45.
4. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol 2001;119:198-207.
5. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal orders. N Engl J Med 1994;331:1480-7.
6. Product labeling. Macugen (pegaptanib). New York: Eyetech Pharmaceuticals and Pfizer, December 2004.
7. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005;22:111-8.
8. VanWijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. JAMA 2005;293:1509-13.
9. Azzouz M, Ralph GS, Storkebaum E, et al. VEGF delivery with retrogradely transported lentiventor prolongs survival in a mouse ALS model. Nature 2004;36:827-35.
10. Ratner M. Genentech discloses safety concerns over Avastin. Natl Biotechnol 2004;22:1198.
11. Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002;22:143-52.
12. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16.
13. D'Amico DJ. Results of the second year of Macugen for the treatment of neovascular AMD (V.I.S.I.O.N.). In: Program and abstracts of the American Society of Retina Specialists 23rd Annual Meeting, Montreal, Canada, July 16-20, 2005.
14. The VEGF inhibition study in ocular neovascularization (V.I.S.I.O.N) clinical trial group. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina 2005;25:815-27.
15. Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005;112: 1747-57.
16. Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitreous injection: a comprehensive review. Retina 2004;24:676-98.